Y
Yanyu Jiang
Researcher at Nankai University
Publications - 10
Citations - 87
Yanyu Jiang is an academic researcher from Nankai University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Chimeric antigen receptor. The author has an hindex of 3, co-authored 10 publications receiving 39 citations.
Papers
More filters
Journal ArticleDOI
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL.
Xiaoyuan He,Xia Xiao,Qing Li,Yanyu Jiang,Yaqing Cao,Rui Sun,Xin Jin,Ting Yuan,Juanxia Meng,Li Ma,Wenyi Lu,Cuicui Lyu,Kaiqi Liu,Mingfeng Zhao +13 more
TL;DR: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models and the discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia is confirmed.
Journal ArticleDOI
HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation.
Xin Jin,Yaqing Cao,Luqiao Wang,Rui Sun,Lin Cheng,Xiaoyuan He,Xia Xiao,Y Y Jiang,Qing Li,Huan Zhang,Wenyi Lu,Cuicui Lyu,Yanyu Jiang,Juanxia Meng,Mingfeng Zhao +14 more
TL;DR: The first-in-human use of HLA-matched allogeneic CAR-T cells (MCART19 cells) before allogenic hematopoietic stem cell transplantation (allo-HSCT) is described and the description of Hla-haploidentical allogeneIC CAR- T cell (HCART19 cell) infusion reported in previous sporadic cases is expanded.
Journal ArticleDOI
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
TL;DR: In this paper, the anti-CD22 CAR-T cell salvage therapy was used in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and acute lymphoid leukemia (B-ALL) patients.
Journal ArticleDOI
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Wenyi Lu,Yunxiong Wei,Yaqing Cao,Xia Xiao,Qing Li,Hairong Lyu,Y Y Jiang,Huan Zhang,Xin Li,Yanyu Jiang,Juanxia Meng,Ting Yuan,Haibo Zhu,Xiaoyuan He,Xin Jin,Rui Sun,Tao Sui,Kaiqi Liu,Mingfeng Zhao +18 more
TL;DR: In this article, the effectiveness and safety of pre-emptive CD19 CAR-T cell treatment is evaluated in MRD-positive B-cell acute lymphoblastic leukemia (B-ALL) patients.
Journal ArticleDOI
Establishment of macrophage model of iron overload in vitro and the injury induced by oxidative stress on macrophage with iron overload
Xiaoli Cao,Mingfeng Zhao,D G Li,Y Xing,Y C Zhang,Jun Chen,X Y He,R Cui,Juanxia Meng,X Xiao,Juan Mu,Yanyu Jiang,R M Wu +12 more
TL;DR: The established model provides a method to explore the mechanism of iron overload on macrophage, and may shed some new light on possible therapeutic target in treating iron overload patients.